An Open Label, Single-arm, Study for Effect of Neoadjuvant Toripalimab (JS001) Before Cystectomy in the treatment of Patients With Muscle-invasive Urothelial Bladder Cancer.
Latest Information Update: 25 Feb 2022
Price :
$35 *
At a glance
- Drugs Toripalimab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- 20 Feb 2022 Results published in the ASCO Genitourinary Cancers Symposium
- 20 Feb 2022 Status changed from not yet recruiting to active, no longer recruiting as per results published in the ASCO Genitourinary Cancers Symposium
- 16 Feb 2022 According to Predicine media release, data from this study will be presented at at the ASCO Genitourinary Cancers Symposium